Market Overview

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences


(NASDAQ:IMGN), a leader in the expanding field of
antibody-drug conjugates (ADCs) for the treatment of cancer, today
announced that the following presentations by Company management at
upcoming investor conferences will be webcast:

  • 20th Annual Rodman & Renshaw Global
    Investment Conference, sponsored by H.C. Wainwright & Co., LLC

    5 at 12:30pm ET
  • Morgan Stanley 16th Annual Global
    Healthcare Conference

    September 13 at 3:30pm ET

A webcast of each presentation will be accessible live through the
"Investors" section of the Company's website,;
a replay will be available in the same location for approximately two

ImmunoGen is developing the next generation
of antibody-drug conjugates (ADCs) to improve outcomes for cancer
patients. By generating targeted therapies with enhanced anti-tumor
activity and favorable tolerability profiles, we aim to disrupt the
progression of cancer and offer our patients more good days. We call
this our commitment to "target a better now." Our lead product
candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate
receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in
Phase 1b/2 testing in combination regimens. Our novel IGN candidates for
hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at

View Comments and Join the Discussion!